Ifidancitinib
Ifidancitinib (ATI-50002) is an orally available, potent and selective inhibitor of JAK kinase 1/3 that disrupts γc cytokine signaling. Ifidancitinib is used in the research of allergy, asthma, and autoimmune diseases[1][2].
Product Specifications
CAS Number
[1236667-40-5]
Product Name Alternative
ATI-50002; ATI-502
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Others
Assay Protocol
https://www.medchemexpress.com/ifidancitinib.html
Purity
98.01
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C1OC2=CC=C(NC3=NC(NC4=CC(C)=C(F)C(OC)=C4)=NC=C3C)C=C2N1
Molecular Formula
C20H18FN5O3
Molecular Weight
395.39
References & Citations
[1]Li, Hui; Heckrodt, Thilo J.; Chen, Yan; Mcmurtrie, Darren John; Taylor, Vanessa; Singh, Rajinder; Ding, Pingyu; Yen, Rose.Preparation of phenylaminopyrimidinylaminooxobenzooxazole derivatives for use as JAK kinase inhibitors. WO2012015972A1|[2]Zhenpeng Dai, et al. Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata. Front Immunol. 2022 Sep 20:13:955038.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
